Profiling of a Novel Orally Bioavailable NMDA Receptor Antagonist in Rodents & Humans Demonstrates Value of Translational Biomarkers
Time: 11:40 am
day: Track 1 AM Day 1
Details:
- In rodents GM-1020 achieves antidepressant-like activity at doses well below those causing motor impairment or disrupting sensory motor processing and has a better therapeutic window than ketamine
- GM-1020 doses that were antidepressant in rats produced marked effects on EEG power spectrum.
- In healthy volunteers doses of GM-1020 that produced similar robust effects on EEG were not associated with sedation, ataxia or dissociation paving the way for evaluating GM- 1020 in patients with MDD
